Article Sidebar
Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Synergistic effects of Yiqi Huazhuo Gushen herbal formula and valsartan on metabolic syndrome complicated with microalbuminuria
Abstract
Purpose: To study the effects of a combination of Yiqi Huazhuo Gushen formula and valsartan on metabolic syndrome (MetS) complicated with microalbuminuria.
Methods: Patients with MetS (100), recruited from Department of the Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital; Department of Integrated Traditional Chinese and Western Medicine, Huashan Hospital, Fudan University; and Department of Endocrinology, Hospital of Integrated Traditional Chinese and Western Medicine in Yueyang, Shanghai University of Traditional Chinese Medicine, were randomly divided into two sets: control group (n = 50) given valsartan treatment, and Chinese herbal medicine (CHF) group (n = 50) given Yiqi Huazhuo Gushen formula in addition to valsartan. Both therapeutic regimens were given once a day for 12 weeks. The parameters measured were conversion rate of microalbuminuria (MA), ratio of urinary albumin to creatinine (UACR), 24- h total volume of urinary protein (24hTP), urinary transferrin, urinary β2 microglobulin, constitutional index (CI), and waist-hip ratio (WHR). Other indices assessed were peak systolic and diastolic pressure (SBP and DBP), mean arterial blood pressure (MABP), fasting plasma glucose (FPG), postprandial 2 h blood glucose (2hPG), glycosylated hemoglobin (GH), steadystate model for insulin resistance (HOMA-IR), total cholesterol (TC), glycerin trilaurate (TG), low density lipoprotein (LDL), and high-density lipoprotein (HDL).
Results: All 100 subjects completed the clinical study. The outcome revealed that compared with 10.00 % in controls, the negative conversion of MA reached 28.00 % in the CHF group (p < 0.050). CHF produced reductions in MA, UACR, BMI, 24hTP and urinary β2 microglobulin (p < 0.05). It also led to marked increases in BMI, WHR, SBP, MAP, FPG, 2hPPG, HbA1c and HOMA-IR, and significant decreases in TG (p < 0.05).
Conclusion: These results suggest that CHF treatment results in alleviation of microalbuminuria and multiple cardiovascular risk factors in metabolic syndrome complicated with microalbuminuria. These effects correlate with improvements in insulin sensitivity and rectification of abnormal fat distribution.
Keywords: Metabolic syndrome, Microalbuminuria, Yiqi Huazhuo Gushen formula, Insulin resistance, Central obesity
